Proline promotes proliferation and drug resistance of multiple myeloma by downregulation of proline dehydrogenase
Jingyu Zhang, Fangming Shi, Xing Liu, Xuan Wu, Cong Hu, Jiaojiao Guo, Qin Yang, Jiliang Xia, Yanjuan He, Gang An, Lugui Qiu, Xiangling Feng, Wen Zhou
Abstract
Amino acids in the bone marrow microenvironment (BMME) are a critical factor for multiple myeloma (MM) progression. Here, we have determined that proline is elevated in BMME of MM patients and links to poor prognosis in MM. Moreover, exogenous proline regulates MM cell proliferation and drug resistance. Elevated proline in BMME is due to bone collagen degradation and abnormal expression of the key enzyme of proline catabolism, proline dehydrogenase (PRODH). PRODH is downregulated in MM patients, mainly as a result of promoter hypermethylation with high expression of DNMT3b. Thus, overexpression of PRODH suppresses cell proliferation and drug resistance of MM and exhibits therapeutic potential for treatment of MM. Altogether, we identify proline as a key metabolic regulator of MM, unveil PRODH governing MM progression and provide a promising therapeutic strategy for MM treatment.